Loading clinical trials...
Loading clinical trials...
Phase 1 Study Using a Plasmid DNA Coding for Emm55 Streptococcal Antigen in Patients With Unresectable Stage III or Stage IV Cutaneous Melanoma
Conditions
Interventions
IFx-Hu2.0
Locations
1
United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Start Date
November 5, 2018
Primary Completion Date
July 10, 2020
Completion Date
November 30, 2020
Last Updated
August 8, 2022
NCT07230613
NCT07148245
NCT03663647
Lead Sponsor
TuHURA Biosciences, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions